Keith Mansford

SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London.

MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ.

Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom.

Part of Takeda Pharmaceutical Co., Ltd., ProScript, Inc. is a company that develops anti-cancer treatments. The company is based in Cambridge, MA. The company was founded by Tom Maniatis. ProScript was acquired by LeukoSite, Inc., part of Takeda Pharmaceutical Co., Ltd. from December 22, 1999 on July 20, 1999 for $3.35 million.

Tel-Aviv University operates as a university in Israel. Its faculties include arts, engineering, science, humanities, law, life science, management, medicine, and social science. The company was founded in 1956 and is headquartered in Ramat Aviv, Israel.

Gilead Connecticut, Inc. manufactures pharmaceuticals and biotechnology chemicals. The firm develops a pipeline of small molecule therapeutics for multiple oncology and immunology-based indications. It focuses on the development of novel kinase inhibitors for the treatment of cancer, autoimmune, and inflammatory diseases. The company was founded in 2000 and is headquartered in Foster City, CA.

Part of Community Health Systems, Inc., Deaconess Hospital is a 313-bed hospital based in Oklahoma City, OK. The hospital provides medical services to patients in the area.

The American Academy of Arts & Sciences is an organization that honors excellence and brings together leaders. The non-profit company is based in Cambridge, MA.

The National Academy of Medicine (United States) is based in Washington and is focused on improving the health and well-being of individuals through various initiatives. These initiatives include the clinician well-being collaborative, which aims to accelerate the implementation of a national plan for health workforce well-being, and the development of a code of conduct for the use of artificial intelligence in health care. The organization also provides resources to support meaningful community engagement in health and health care programs and policies. Recently, the National Academy of Medicine announced the appointment of Mandy Cohen, a member of the organization, as the director of the Centers for Disease Control and Prevention. Additionally, the organization has released a publication celebrating 50 years of progress in biomedical science, health, and health care.

CureTech Ltd. operates as a biotechnology company. It develops novel and immune modulating products for the treatment and control of cancer. The company was founded by Michael Schickler in 1995 and is headquartered in Yavne, Israel.

Sancilio & Co., Inc. operates as specialty pharmaceutical company. It develops and markets based products including those based on the proprietary Advanced Lipid Technologies platform. The company was founded by Frederick D. Sancilio in 2005 and is headquartered in Riviera Beach, FL.

Accellta Ltd. offers solutions for stem cell culturing. Its portfolio include pluripotent stem cell culturing, human foreskin-derived feeder cells, growth media for feeder-free culturing of hPSC, stem cell expansion in suspension, stem cell culturing as single-cells in bioreactors, stem-cell controlled differentiation, and medium formulation. The company was founded in 2012 and is headquartered in Haifa, Israel.

UBS Oncology Impact Fund is an American private company located in Cambridge, MA, with a presence in the Cayman Islands, that functions as a family of funds.

Cardurion Pharmaceuticals LLC is a cardiovascular biotechnology company, which engages in the development of therapeutics for the treatment of heart failure and cardiovascular diseases. The company was founded by Michael E. Mendelsohn in 2017 and is headquartered in Boston, MA.

FameWave Ltd. is a biopharmaceutical company engaging in the development of medications for the treatment of cancer. Its product is CM-24. The company was founded on July 2, 2017 and is headquartered in Tel Aviv, Israel.

Matrivax Research & Development Corp. is developing human vaccines for the prevention and treatment of life-threatening bacterial diseases. Its pipeline includes two vaccine candidates implementing proprietary streptococcus pneumoniae and clostridium difficile protective antigens. The company was founded in October 2007 and is headquartered in Boston, MA.

Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes.

MPM BioImpact LLC (MPM BioImpact) is a venture capital firm a subsidiary of MPM Bioimpact Inc founded in 1996. The firm is headquartered in Cambridge, Massachusetts.

Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada.

Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market.